Abstract: The present disclosure relates to reagents (antigenic and/or immunogenic reagents) and kits that are useful in a variety of in vitro, in vivo, and ex vivo methods including, e.g., methods for inducing an immune response, or for generating an antibody, in a subject. The reagents described herein can be used in the treatment or prevention of HIV-1 infections. In addition, the disclosure provides methods and compositions useful for designing (or identifying) an agent that binds to an membrane proximal external region (MPER) of an HIV-1 gp160 polypeptide or an agent that inhibits the fusion of an HIV-1 particle to a cell.

Abstract: The present invention relates to compositions containing one or more proteins, one or more polysaccharides and one or more fat-soluble active ingredients and their use for the enrichment, fortification and/or coloration of food beverages, animal feed and/or cosmetics.

Abstract: The present invention relates to the identification of molecular mechanisms associated with multidrug resistance (MDR) in fungal infections. More specifically, fungi harbor a nuclear receptor-like pathway controlling MDR, which represents a novel therapeutic target for the treatment of MDR in pathogenic fungi such as C. glabrata.

Abstract: A composition and method for inhibiting proliferation of a tumor cell compared to a non-tumor cell. Also described are methods of screening for a composition that inhibits cap-dependent translation compared to cap-independent translation of proteins.

Abstract: (Modified) rice endosperm protein is used as novel protective hydrocolloid for active ingredients, especially fat-soluble active ingredients and/or colorants. Included are compositions comprising (modified) rice endosperm protein and at least one active ingredient and to their manufacture, as well as to the (modified) rice endosperm protein itself and its manufacture. These compositions are used for the enrichment, fortification and/or coloration of food, beverages, animal feed, personal care or pharmaceutical compositions, and to food, beverages, animal feed, personal care and pharmaceutical compositions containing such a (modified) rice endosperm protein and such a composition, respectively.

Abstract: The present invention relates to compositions containing (fat-soluble) active ingredients and/or colorants in a matrix based on modified plant gums, i.e. plant gums that have been submitted to hydrolysis to degrade either the protein portion and/or where appropriate, the polysaccharide, and to a process for preparing these compositions as well as to modified plant gums, whose protein part is hydrolysed up to a degree of about 30%, preferably to a degree of from about 0.05 to about 30%, and/or whose polysaccharide part is hydrolysed up to a degree of about 50%, a process for the manufacture thereof and such modified plant gums themselves. The present invention further relates to the use of the compositions of this invention for the enrichment, fortification and/or for the coloration of food, beverages, animal feed, cosmetics and pharmaceutical compositions and to such food, beverages, animal feed, cosmetics and pharmaceutical compositions themselves.

Abstract: The invention relates to an apparatus and a process for the preparation of anhydrous or substantially anhydrous formic acid. This apparatus is constructed partly or entirely of substantially zirconium-free materials. The extractant employed is a liquid of the general formula I where the radicals R1 and R2 are alkyl, cycloalkyl, aryl or aralkyl groups, or R1 and R2 jointly, together with the N atom, form a heterocyclic 5- or 6-membered ring, and only one of the radicals is an aryl group, and where R3 is hydrogen or a C1–C4-alkyl group. The apparatus has a synthesis reactor (6), a hydrolysis reactor (1), three distillation devices (2,4,5) and an extraction device (3).

Abstract: A human CD2 cytoplasmic tail binding protein, CD2BP2, is described, as well as the nucleic acids encoding the protein. Also described are expression vectors and recombinant host cells comprising nucleic acids encoding the CD2BP2 protein, and methods of use for the CD2BP2 protein and nucleic acids encoding the CD2BP2 protein.

Abstract: A sprocket chain with a plurality of links (1) pivotally bound together via pins (2). To enable the introduction of power, power input elements (5) are provided, the input elements (5) being separate from the pins (2), the end faces (6) of the input elements (5) possessing at least two contact surfaces (7) in the running direction of the sprocket chain.

Abstract: The invention relates to a process for obtaining anhydrous or substantially anhydrous formic acid in which, during the work-up, a compound of the general formula I where the radicals R1 and R2 are alkyl, cycloalkyl, aryl or aralkyl groups, or R1 and R2 jointly, together with the N atom, form a heterocyclic 5- or 6-membered ring, and only one of the radicals is an aryl group, and where R3 is hydrogen or a C1-C4-alkyl group, is employed simultaneously as extractant for formic acid and as antifoam for a distillation process.

Abstract: The invention relates to a method for the large scale production of patterned active surfaces for bioconjugation comprising the steps of:

Abstract: The invention relates to a process for the preparation of anhydrous or substantially anhydrous formic acid. The process has the special feature that a liquid of the general formula I where the radicals R1 and R2 are alkyl, cycloalkyl, aryl or aralkyl groups, or R1 and R2 jointly, together with the N atom, form a heterocyclic 5- or 6-membered ring, and only one of the radicals is an aryl group, and where R3 is hydrogen or a C1-C4-alkyl group, employed as extractant is also employed as washing liquid for the offgases produced in the process.

Abstract: Isolated peptide fragments of the conserved regulatory domain of NFAT protein capable of inhibiting protein-protein interaction between calcineurin and NFAT, or a biologically active analog thereof are described. Isolated polynucleotides and gene therapy vectors encoding such peptide fragments are also described. In addition, methods for treating immune-related diseases or conditions and methods for high throughput screening of candidate agents are described. Pharmaceutical compositions are also provided.

Abstract: The invention relates to an apparatus and a process for the preparation of anhydrous or substantially anhydrous formic acid. This apparatus is constructed partly or entirely of substantially zirconium-free materials.

Abstract: The present invention provides methods of stabilizing proteins in solution. More particularly, the present invention provides a method of solublizing and stabilizing a target protein in solution by forming a fusion protein of the target protein with a small solubility and stability enhancing tag. The present invention also features methods of determining the structure of a target protein using a fusion protein to stabilize the target protein in solution.

Abstract: The invention relates to a process for the preparation of anhydrous or substantially anhydrous formic acid.

Abstract: The invention relates to a process for obtaining anhydrous or substantially anhydrous formic acid in which, during the work-up, a compound of the general formula I 1

Abstract: A human CD2 cytoplasmic tail binding protein, CD2BP2, is described, as well as the nucleic acids encoding the protein. Also described are expression vectors and recombinant host cells comprising nucleic acids encoding the CD2BP2 protein, and methods of use for the CD2BP2 protein and nucleic acids encoding the CD2BP2 protein.

Abstract: Described here is a process for controlling a passenger protection system by means of a CPU in conjunction with acceleration signals and the existence of at least one trigger inhibiting signal from a manually operated trigger inhibitor or a seat occupancy detection device. This process prevents errors in the CPU. For this purpose, monitoring of the trigger inhibitor and the seat occupancy detection devices is provided in an evaluation unit parallel to the CPU, in order to set an ignition inhibiting signal, as soon as at least one of these devices sets a trigger inhibiting signal. The ignition inhibiting signal influences the inhibiting device located between the CPU and the passenger protection device, disabling the trigger. This makes it impossible for an error in the CPU to trigger the passenger protection device inadvertently.

Abstract: Purified and crystallized riboflavin is prepared by a process that includes dissolving needle-shaped riboflavin of the stable modification A form in an aqueous mineral acid solution at a temperature not exceeding about 30.degree. C. with intensive intermixing. Active charcoal is then added to the resulting solution. After adsorption of the dissolved impurities from the solution onto the active charcoal, the solution containing the active charcoal is subjected to counter-current filtration over a ceramic membrane having a pore size of about 20 to about 200 nm. The resulting filtrate is treated with a five- to ten-fold amount of water (vol./vol.) at a temperature not exceeding about 30.degree. C. The resulting precipitated, spherical crystals of riboflavin are then separated by centrifugation or filtration. If desired, the spherical crystals of riboflavin may be washed with water and subsequently dried.